<DOC>
	<DOCNO>NCT03072953</DOCNO>
	<brief_summary>The purpose Phase 2a , open label , proof-of-concept clinical study ass efficacy safety etrasimod ( APD334 ) patient Pyoderma Gangrenosum .</brief_summary>
	<brief_title>Efficacy Safety APD334 Patients With Pyoderma Gangrenosum</brief_title>
	<detailed_description />
	<mesh_term>Pyoderma Gangrenosum</mesh_term>
	<mesh_term>Pyoderma</mesh_term>
	<criteria>1 . Male female ( 1880 year ) . 2 . Able provide sign informed consent prior study related procedure conduct . 3 . Diagnosis PG active , nonhealing ulcer . 4 . Considered stable health opinion investigator determine : 1 . A screening physical examination clinically significant abnormality unrelated PG . 2 . Vital sign screen : pulse rate ≥ 55 bpm , systolic blood pressure ≥ 90 mmHg , diastolic blood pressure ≥ 55 mmHg . 3 . Liver function test ( alanine aminotransferase/aspartate aminotransferase , bilirubin alkaline phosphatase ) &lt; 2x upper limit normal . 4 . All prestudy clinical laboratory finding within normal range , outside normal range deem clinically significant opinion investigator exemption leucopenia lymphopenia please refer exclusion criterion 24 . 5 . No clinical abnormality note the12lead electrocardiogram opinion investigator ( Refer also exclusion criterion 13 ) . 6 . No evidence macular edema ophthalmology evaluation ( performed ophthalmologist ) , support optical coherence tomography , available ( dependent site capability ) screening . 5 . Eligible male female patient must agree participate conception process ( i.e . active attempt let female partner become pregnant impregnate , sperm donation , oocyte donation , vitro fertilization ) least 30 day last dose study drug . Nonsterile patient sexually active must take adequate contraception measure . 1 . Clinically significant infection judge investigator end date le 6weeks prior treatment start ( Day 1 ) . In case infection require hospitalization intravenous antimicrobial therapy , opportunistic infection , infection must end least 8 week prior Day 1 . 2 . Infection hepatitis C virus anytime past ; confirm active infection hepatitis B virus screening . 3 . History severe renal severe hepatic impairment . 4 . Current active latent tuberculosis ( TB ) . 5 . A positive diagnostic TB test screening . 6 . Exposure Bcell Tcell target therapy ( natalizumab , rituximab , abatacept ) within 5 halflives prior Day 1 . 7 . Exposure immunosuppressive , immunomodulating antineoplastic agent . 8 . Receipt investigational agent within 30 day 5 half life ( whichever longer ) , prior Day 1 . 9 . Use moderate strong inhibitor CYP2C9 . 10 . Abnormal force expiratory volume ( FEV1 ) force vital capacity ( FVC ) . 11 . Any known history congenital acquire immunodeficiency . 12 . Recent history ( within 6 month screen visit ) cardio cerebrovascular disease , acute coronary syndrome , myocardial infarction , unstable angina , cerebrovascular accident , include transient ischemic attack . 13 . History presence cardiac arrhythmia , conduction system disease , use Class Ia Class III anti arrhythmic agent , baseline QTc ≥ 500 msec . 14 . Congestive heart failure ( NYHA III NYHA IV ) 15 . Any surgical procedure require general anesthesia within 30 day prior Day 1 plan undergo major surgery study period . 16 . History retinal macular edema . 17 . History sign symptom progressive multifocal leukoencephalopathy ( PML ) assess PML checklist screen . 18 . History one episode herpes zoster episode disseminate zoster . 19 . Patients without documented positive varicella zoster virus ( VZV ) IgG antibody status patient complete VZV vaccination within 6 week prior Day 1 . 20 . Receipt live vaccine within 6 week prior Day 1 . 21 . History lymphoproliferative disorder , lymphoma , leukemia , myeloproliferative disorder , multiple myeloma . 22 . History malignancy except adequately treat basal cell skin cancer situ carcinoma cervix uterus completely excise document , clear margin . 23 . History severe allergic anaphylactic reaction require medical attention . 24 . Leukopenia lymphopenia screening . 25 . Current recent history ( within 1 year prior Day 1 ) alcohol dependence illicit drug use . 26 . Active psychiatric problem , investigator 's opinion , may interfere compliance study procedure . 27 . History clinically significant medical condition , investigator 's opinion , would preclude patient safe participation study . 28 . Inability attend study visit comply study procedure . 29 . Prior exposure etrasimod ( APD334 ) prior participation study etrasimod ( APD334 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>